{"product_id":"drug-repositioning-bringing-new-life-to-shelved-assets-and-existing-drugs-hardback-9780470878279","title":"Drug Repositioning; Bringing New Life to Shelved Assets and Existing Drugs (Hardback) 9780470878279","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eDrug Repositioning\u003c\/font\u003e\u003cbr\u003e\r\n\u003cfont size=\"5\"\u003eBringing New Life to Shelved Assets and Existing Drugs\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\r\n\u003cp\u003e\u003cfont size=\"4\"\u003eMichael J. Barratt (Author), Donald E. Frail (Author)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470878279, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 6 July 2012\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e498 pages\u003cbr\u003e24.1 x 16.5 x 3.2 cm, 1.361 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e“Overall, this book is so complete that it is a must read for all the players in drug repositioning, not only  researches or drug developers, but also business development specialist, investors, venture capital firms, academia and regulators that need a compressive description that will satisfy novice and more experienced professionals.”  (\u003ci\u003eChemMedChem\u003c\/i\u003e, 1 March 2013)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003e\u003cp\u003e\u003cb\u003eThe how's and why's of successful drug repositioning \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDrug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDrug Repositioning\u003c\/i\u003e is divided into three parts:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003e\u003cb\u003ePart 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations,\u003c\/b\u003e examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs.\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003e\u003cb\u003ePart 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs,\u003c\/b\u003e sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents.\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003e\u003cb\u003ePart 3, Academic and Non-Profit Initiatives \u0026amp; the Role of Alliances in the Drug Repositioning Industry\u003c\/b\u003e, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return.\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits.\u003c\/p\u003e \u003cp\u003eWith this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development.\u003c\/p\u003e\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e\u003cp\u003eAbout the Editors xv\u003c\/p\u003e \u003cp\u003eAcknowledgments xvii\u003c\/p\u003e \u003cp\u003eContributors xix\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003cbr\u003e Michael J. Barratt and Donald E. Frail\u003c\/p\u003e \u003cp\u003eReferences 5\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart I. Drug Repositioning: Business Case, Strategies, and Operational Consideration 7\u003cbr\u003e \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Drug Repositioning: The Business Case and Current Strategies to Repurpose Shelved Candidates and Marketed Drugs 9\u003cbr\u003e \u003ci\u003eJohn Arrowsmith and Richard Harrison\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e 2. Opportunities and Challenges Associated with Developing Additional Indication for Clinical Development Candidates and Marketed Drugs 33\u003cbr\u003e \u003ci\u003eDonald E. Frail and Michael J. Barratt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3. Clinical and Operational Considerations in Repositioning Marketed Drugs and Drug Candidates 53\u003cbr\u003e \u003ci\u003eDamian O’Connell, David J. Sequeira, and Maria L. Miller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4. Regulatory Considerations and Strategies for Drug Repositioning 65\u003cbr\u003e \u003ci\u003eKen Phelps\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart II. Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs 89\u003cbr\u003e \u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e5. Computational and Bioinformatic Strategies for Drug Repositioning Drugs 91\u003cbr\u003e \u003ci\u003eRichard Mazzarella and Craig Webb\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6. Mining Scientific and Clinical Databases to Identify Novel Uses for Existing Drugs 137\u003cbr\u003e \u003ci\u003eChristos Andronis, Anuj Sharma, Spyros Deftereos, Vassilis Virvilis, Ourania Konstanti, Andreas Persidis, and Aris Persidis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7. Predicting the Polypharmacology of Drugs: Identifying New Uses through Chemoinformatics, Structural Informatics, and Molecular Modeling-Based Approaches 163\u003cbr\u003e \u003ci\u003eLi Xie, Sarah L. Kinnings, Lei Xie, and Philip E. Bourne\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8. Systematic Phenotypic Screening for Novel Synergistic Combinations: A New Paradigm for Repositioning Existing Drugs 207\u003cbr\u003e \u003ci\u003eMargaret S. Lee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9. Phenotypic \u003ci\u003eIn Vivo\u003c\/i\u003e Screening to Identify New, Unpredicted Indications for Existing Drugs and Drug Candidates 253\u003cbr\u003e \u003ci\u003eMichael S. Saporito, Christopher A. Lipinski, and Andrew G. Reaume\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10. Old Drugs Yield New Discoveries: Examples from the Prodrug , Chiral Switch, and Site-Selective Deuteration Strategies 291\u003cbr\u003e \u003ci\u003eAdam J. Morgan, Bhaumik A. Pandya, Craig E. Masse, and Scott L. Harbeson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart III. Academic and Nonprofit Initiatives and the Role of Alliances in the Drug Repostioning Industry 345\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11. Repurposing Drugs for Tropical Disease: Case Studies and Open-Source Screening Initiatives 347\u003cbr\u003e \u003ci\u003eCurtis R. Chong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12. Drug Repositioning Efforts by Nonprofit Foundations 389\u003c\/p\u003e \u003cp\u003e13. Business Development Strategies in the Repositioning Industry 433\u003cbr\u003e \u003ci\u003eAris Persidis and Elizabeth T. Stark\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14. A Case Study in Drug Repositioning: Sosei 445\u003cbr\u003e \u003ci\u003eAkinori Mochizuki and Makiko Aoyama\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAppendix Additional Drug Repositioning Resources and Links 457\u003cbr\u003e \u003ci\u003eMark A. Mitchell and Michael J. Barratt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 469\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52278087188760,"sku":"9780470878279","price":88.79,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470878279.jpg?v=1781458089","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/drug-repositioning-bringing-new-life-to-shelved-assets-and-existing-drugs-hardback-9780470878279","provider":"Freshly Printed Books","version":"1.0","type":"link"}